Recent IXHL News
- Form 8-K - Current report • Edgar (US Regulatory) • 09/10/2024 12:00:12 PM
- Incannex Healthcare Announces Strategic Financing for up to $60 Million with Arena Investors • GlobeNewswire Inc. • 09/10/2024 12:00:00 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 09/10/2024 11:30:22 AM
- Form RW - Registration Withdrawal Request • Edgar (US Regulatory) • 09/10/2024 11:00:07 AM
- FDA Review of PsiGAD2 IND complete; clinical trial for Psilocybin Assisted Psychotherapy in Patients with Generalised Anxiety Disorder to Proceed • GlobeNewswire Inc. • 08/05/2024 11:30:00 AM
- Form 8-K - Current report • Edgar (US Regulatory) • 07/30/2024 01:00:09 PM
- Dosing completed in 115 participant bioavailability/bioequivalence clinical trial for proprietary sleep apnea drug candidate IHL-42X • GlobeNewswire Inc. • 07/30/2024 11:30:00 AM
- Form 8-K - Current report • Edgar (US Regulatory) • 05/30/2024 12:30:34 PM
- Patient dosing commenced in RePOSA Phase 2/3 Clinical Trial Protocol to Assess IHL-42X Drug in Patients with Obstructive Sleep Apnea • GlobeNewswire Inc. • 05/30/2024 11:30:00 AM
- Incannex Complete Successful Pre-IND Meeting with the FDA for CannQuit-O for treatment of opioid use disorder • GlobeNewswire Inc. • 05/07/2024 11:30:00 AM
- Incannex Healthcare Inc. Quarterly Update, Q1 2024 • GlobeNewswire Inc. • 04/16/2024 12:00:00 PM
- Incannex Announces Positive Topline Results from Phase 2 Psi-GAD1 Clinical Trial of Psilocybin in Generalised Anxiety Disorder • GlobeNewswire Inc. • 02/28/2024 12:30:00 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 02/16/2024 01:00:11 PM
- Incannex Completes Successful Pre-IND Meeting with the FDA for CannQuit-N; a Novel Solution for Tobacco Smoking Cessation • GlobeNewswire Inc. • 02/16/2024 12:30:00 PM
- Form 10-Q - Quarterly report [Sections 13 or 15(d)] • Edgar (US Regulatory) • 02/14/2024 11:16:51 AM
- Form 8-K - Current report • Edgar (US Regulatory) • 02/01/2024 12:30:16 PM
- Clarion Clinics Open for Psychedelic-Assisted Treatments • GlobeNewswire Inc. • 02/01/2024 12:30:00 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 01/24/2024 09:30:18 PM
- Incannex Commences Dosing in Phase 2 Clinical Trial Assessing IHL-675A in Patients with Rheumatoid Arthritis • GlobeNewswire Inc. • 01/24/2024 09:05:00 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 01/18/2024 02:08:33 PM
- Incannex Completes Dosing and Therapy in Phase 2 “PsiGAD” Clinical Trial Assessing Psilocybin-assisted Psychotherapy for Generalized Anxiety Disorder; Data Analysis Commences • GlobeNewswire Inc. • 01/18/2024 01:22:34 PM
- Incannex Receives IRB Approval for the RePOSA Phase 2/3 Clinical Trial Protocol to Assess IHL-42X Drug in Patients with Obstructive Sleep Apnea • GlobeNewswire Inc. • 01/17/2024 12:30:00 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 01/17/2024 11:05:45 AM
- Form 8-K - Current report • Edgar (US Regulatory) • 12/22/2023 11:07:13 AM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 12/22/2023 01:54:45 AM
VHAI - Vocodia Partners with Leading Political Super PACs to Revolutionize Fundraising Efforts • VHAI • Sep 19, 2024 11:48 AM
Dear Cashmere Group Holding Co. AKA Swifty Global Signs Binding Letter of Intent to be Acquired by Signing Day Sports • DRCR • Sep 19, 2024 10:26 AM
HealthLynked Launches Virtual Urgent Care Through Partnership with Lyric Health. • HLYK • Sep 19, 2024 8:00 AM
Element79 Gold Corp. Appoints Kevin Arias as Advisor to the Board of Directors, Strengthening Strategic Leadership • ELMGF • Sep 18, 2024 10:29 AM
Mawson Finland Limited Further Expands the Known Mineralized Zones at Rajapalot: Palokas step-out drills 7 metres @ 9.1 g/t gold & 706 ppm cobalt • MFL • Sep 17, 2024 9:02 AM
PickleJar Announces Integration With OptCulture to Deliver Holistic Fan Experiences at Venue Point of Sale • PKLE • Sep 17, 2024 8:00 AM